Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  American Journal of Psychiatry

• Publication date

  2008-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1176/appi.ajp.2008.08040482PMID 18829880PMCID PMC2742969
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9.

  2010cited by this paper
• Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis.

  2009cited by this paper
• Major depression after breast cancer: a review of epidemiology and treatment.

  2008cited by this paper
• A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?

  2008cited by this paper
• A phase III trial evaluating three doses of citalopram for hot flashes: NCCTG trial N05C9

  2008cited by this paper
• Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen.

  2008cited by this paper
• Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

  2007cited by this paper
• Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

  2007cited by this paper
• Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer.

  2007cited by this paper
• Comparison of Duloxetine, Escitalopram, and Sertraline Effects on Cytochrome P450 2D6 Function in Healthy Volunteers

  2007cited by this paper
• Clinical update: new treatments for hot flushes.

  2007cited by this paper
• Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study of Sertraline (Zoloft) for the Treatment of Hot Flashes in Women with Early Stage Breast Cancer Taking Tamoxifen

  2006cited by this paper
• Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment

  2006cited by this paper
• The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

  2006cited by this paper
• Management of Miscarriage: Expectant, Medical, or Surgical? Results of Randomised Controlled Trial (Miscarriage Treatment [MIST] Trial)

  2006cited by this paper
• Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

  2005cited by this paper
• Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial.

  2005cited by this paper
• Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

  2005cited by this paper
• Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

  2005cited by this paper
• CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

  2005cited by this paper
• Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen

  2004cited by this paper
• Effects of the CYP 2D6 Genotype and Cigarette Smoking on the Steady‐State Plasma Concentrations of Fluvoxamine and Its Major Metabolite Fluvoxamino Acid in Japanese Depressed Patients

  2003cited by this paper
• Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.

  2003cited by this paper
• Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

  2003cited by this paper
• Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

  2003cited by this paper
• Phase III evaluation of fluoxetine for treatment of hot flashes.

  2002cited by this paper
• Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.

  2002cited by this paper
• Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study.

  2001cited by this paper
• Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.

  2000cited by this paper
• A 40-year perspective on the prevalence of depression: the Stirling County Study.

  2000cited by this paper
• Screening for anxiety and depression in women with breast cancer. Psychiatry and medical oncology gear up for managed care.

  1999cited by this paper
• The Relationship Between Tamoxifen, Estrogen, and Depressive Symptoms

  1999cited by this paper
• Tamoxifen in the treatment of breast cancer.

  1998cited by this paper
• Tamoxifen in the Treatment of Breast Cancer

  1998cited by this paper
• Tamoxifen in the treatment of breast cancer.

  1988cited by this paper

• Clinical efficacy and multi-omics analysis of Si–Ni–San for depression treatment in breast cancer patients: a randomized, double-blind, placebo-controlled, crossover trial

  2026cites this paper
• Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic.

  2025cites this paper
• Alternativas al tratamiento hormonal de la menopausia

  2025cites this paper
• Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

  2024cites this paper
• Vitamin D inhibits tamoxifen-induced non-alcoholic fatty liver disease through a nonclassical estrogen receptor/liver X receptor pathway.

  2024cites this paper
• Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon

  2024cites this paper
• Menopausia

  2023cites this paper
• Breast cancer treatment disparities in patients with severe mental illness: A systematic review and meta‐analysis

  2023cites this paper
• A case study of a patient‐centered reverse translational systems‐based approach to understand adverse event profiles in drug development

  2022cites this paper
• [Non-hormonal alternatives for the management of menopausal hot flushes. CNGOF and GEMVi clinical practice guidelines].

  2021cites this paper
• Serotoninergic receptor ligands improve Tamoxifen effectiveness on breast cancer cells

  2021cites this paper
• The Quality of Life of Patients with Suspected Lung Cancer before and after Bronchoscopy and the Effect of Mirtazapine on the Depressive Status

  2020cites this paper
• The Psychopharmacological Management of Depression in Patients with Cancer

  2020cites this paper
• Traitements non hormonaux des bouffées vasomotrices

  2019cites this paper
• The use of antidepressants in oncology: a review and practical tips for oncologists

  2018influential citation
• Translational High‐Dimensional Drug Interaction Discovery and Validation Using Health Record Databases and Pharmacokinetics Models

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• Risk of cancer death by comorbidity severity and use of adjuvant chemotherapy among women with locoregional breast cancer.

  2018cites this paper
• Translational Biomedical Informatics and Pharmacometrics Approaches in the Drug Interactions Research

  2018cites this paper
• The most frequent drug interactions in oncology

  2018cites this paper
• Nejčastější lékové interakce u protinádorových léčiv

  2018cites this paper
• Light therapy and mood in breast cancer

  2018cites this paper
• Role of Brf1 interaction with ERα, and significance of its overexpression, in human breast cancer

  2017influential citation
• Pharmacological Therapy for Vasomotor Symptoms in Breast Cancer Survivors

  2017cites this paper
• Tamoxifen Therapy and CYP 2 D 6 Genotype

  2016cites this paper
• Psychiatric Symptoms and Psychosocial Problems in Patients with Breast Cancer.

  2016cites this paper
• Tamoxifen Therapy and CYP2D6 Genotype

  2016cites this paper
• Interactions médicamenteuses entre les psychotropes et les thérapies pharmacologiques en oncologie : quelles modalités de prescription ?

  2015cites this paper
• Cancer-related fatigue: impact on patient quality of life and management approaches

  2015cites this paper
• The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity

  2015cites this paper
• Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.

  2015cites this paper
• Drug interactions between antineoplastic and antidepressant agents: analysis of patients seen at an oncology clinic at a general hospital.

  2015cites this paper
• Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis

  2015cites this paper
• Cancer-related fatigue: impact on patient quality of life and management approaches

  2015cites this paper
• Effect of age on drug metabolism in women with breast cancer

  2015influential citation
• Therapiebedingte Depressionen bei malignen Erkrankungen

  2014cites this paper
• Combination Treatment of Tamoxifen with Risperidone in Breast Cancer

  2014cites this paper
• Fluoxetine modulates breast cancer metastasis to the brain in a murine model

  2014cites this paper
• Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: A review

  2014cites this paper
• Breast cancer version 3.2014.

  2014cites this paper
• Major depressive disorder in breast cancer: a critical systematic review of pharmacological and psychotherapeutic clinical trials.

  2014cites this paper
• Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjects.

  2014cites this paper
• General Principles of Psychopharmacological Treatment in Psycho-Oncology

  2014cites this paper
• The development and application of a polymerase chain reaction (PCR) based assay to determine the impact of genetic variation in South African patients diagnosed with depression

  2014cites this paper
• Harnessing pharmacological knowledge for personalized medicine and pharmacotyping: Challenges and lessons learned

  2014cites this paper
• The development and application of a polymerase chain reaction (PCR) based assay to determine the impact of genetic variation in South African patients diagnosed with depression

  2014cites this paper
• Implicación del factor de transcripción Nrf2 en trastornos depresivos

  2014cites this paper
• NCCN Breast Cancer Version 3 . 2014 Clinical Practice Guidelines in Oncology

  2014cites this paper
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines

  2014cites this paper
• Relationship of oestrogen receptor status to depressive symptoms and quality of life in breast cancer patients

  2013cites this paper
• [Anxiogenic and depressogenic side-effects of non-psychiatric drugs].

  2013cites this paper
• Nem pszichiátriai gyógyszerek szorongást és depressziót kiváltó mellékhatásai

  2013cites this paper
• Medication Errors in Adults—Case #4: Chemotherapy Drug Interactions

  2013cites this paper
• Psychopharmacology in Psycho-oncology

  2013cites this paper
• Transcranial direct current stimulation and repetitive transcranial magnetic stimulation in consultation-liaison psychiatry

  2013cites this paper
• PharmGKB summary: tamoxifen pathway, pharmacokinetics

  2013cites this paper
• Prescribing Patterns of Antidepressants and Their Associated Factors in Breast Cancer Patients

  2013cites this paper
• Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes

  2013cites this paper
• Pharmacogenomics of breast cancer therapy: an update.

  2013cites this paper
• Antidepressants and tamoxifen: interaction concerns

  2013cites this paper
• Pharmacological treatment of depression in women with breast cancer: a systematic review

  2013influential citation
• CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy

  2013cites this paper
• Tamoxifen pharmacokinetics and pharmacogenetics in endocrine sensitive breast cancer patients

  2013cites this paper
• 9. Psychopharmacological Interventions

  2012cites this paper
• Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-week, open-label prospective trial.

  2012cites this paper
• Pharmacogenetic screening for drug therapy: from single gene markers to decision making in the next generation sequencing era.

  2012cites this paper
• Pharmacogenomics and Nanotechnology Toward Advancing Personalized Medicine

  2012cites this paper
• Traitement des bouffées de chaleur après cancer du sein

  2012cites this paper
• Psychiatric Problems in Patients with Breast Cancer

  2012cites this paper
• Breast cancer and antidepressant use.

  2012cites this paper
• Concurrent treatment with tamoxifen and CYP2D6 inibitors: clinical significance of drug interactions

  2012cites this paper
• [Management of hot flushes for breast cancer survivors].

  2012cites this paper
• Aromatase inhibitors and mood disturbances

  2012cites this paper
• Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004–2010

  2012cites this paper
• [Influence of antidepressant pharmacotherapy on the course of cancer].

  2012influential citation
• Infusion of pharmacogenetics into cancer care.

  2011cites this paper
• [Antagonism of tamoxifen and antidepressants among women with breast cancer].

  2011cites this paper
• Tamoxifen-Ssris Interaction: Clinical Manifestations of Inhibition and Lack of Inhibition of Cyp2D6

  2011cites this paper
• Depressogenic effects of medications: a review

  2011cites this paper
• Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes.

  2011cites this paper
• Tamoxifeno y antidepresivos: ¿Antagonistas en la prevención del cáncer de mama?

  2011cites this paper
• Invasive Breast CancerPractice Guidelines in Oncology

  2011cites this paper
• Pharmacogenetic Testing: Time for Clinical Practice Guidelines

  2011cites this paper
• Putting evidence into practice: evidence-based interventions for hot flashes resulting from cancer therapies.

  2011cites this paper
• Do antidepressants reduce the effectiveness of tamoxifen? †

  2011cites this paper
• Relapse after switching antidepressants because of tamoxifen use: a report of 2 cases.

  2011cites this paper
• Psychische Störungen bei somatischen Krankheiten

  2011cites this paper
• The Impact of Cancer and Its Treatments on the Sexual Self of Young Adult Cancer Survivors and as Compared to Their Healthy Peers

  2011cites this paper
• Invasive breast cancer.

  2011cites this paper
• 27 – Patients with Cancer

  2010cites this paper
• Pharmacotherapy of Depression in People with Cancer

  2010cites this paper
• Les antidépresseurs en oncologie : spécificités et particularités

  2010cites this paper
• Supportive Care in Elderly Cancer Patients

  2010cites this paper
• Interaction pharmacocinétique entre les inhibiteurs sélectifs de la recapture de la sérotonine et le tamoxifène : où en est-on ?

  2010cites this paper
• Interaction of serotonin reuptake inhibitors with tamoxifen

  2010cites this paper
• Risk of Recurrent Breast Cancer With SSRI/Tamoxifen Interaction

  2010cites this paper
• Women at a dangerous intersection: diagnosis and treatment of depression and related disorders in patients with breast cancer.

  2010cites this paper
• Management of hot flashes in women with breast cancer

  2010cites this paper
• Psychiatric pharmacogenomic testing in clinical practice

  2010cites this paper
• Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen

  2010cites this paper